CAN-PRIME Study Launch
Neuralink’s First Clinical Trial in Canada is Open for Recruitment
We are thrilled to announce that we have received approval from Health Canada to launch the CAN-PRIME Study, our first international trial. This investigational medical device trial for our fully-implantable, wireless brain-computer interface (BCI) builds upon the successes of our ongoing PRIME Study in the U.S. and marks an important step towards developing innovative BCI technology that has the potential to transform the lives of individuals with neurological disorders around the world.
Similar to the PRIME Study, the CAN-PRIME Study aims to evaluate the safety of our implant and surgical robot and assess the initial functionality of our BCI for enabling people with quadriplegia to control external devices with their thoughts. The trial is currently open to Canadian residents with limited or no ability to use both hands due to amyotrophic lateral sclerosis (ALS) or cervical spinal cord injury.
To learn more about the CAN-PRIME Study, please visit our listing on clinicaltrials.gov. Please visit our Patient Registry to apply to participate in the trial.